The first real jump in the stock occurred in early Oct 2011 when Merck gave back the anti-HGF program unexpectedly after their acquisition of Schering Plough.
Today, AVEO (name was changed in 2005) has an interesting multi-kinase inhibitor tivozanib in Phase 3 for renal cell cancer, and their second program is an anti-HGF mAb.